Browsing Tag
CMS
14 posts
CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m
CVS Health's Aetna to pay $117.7M over Medicare Advantage diagnosis code fraud. Read what this means for CVS stock and managed care enforcement.
CMS LCD withdrawal gives Kerecis fish-skin platform a strategic edge in outpatient wound care reimbursement
CMS pulled back LCD restrictions on wound grafts. Find out how Kerecis' fish-skin platform is gaining a strategic edge as reimbursement reforms unfold.
Why Merit Medical is launching WRAPSODY early despite Medicare payment setback
Find out how Merit Medical is revamping its commercial approach for WRAPSODY after a Medicare delay — the dialysis-device story you need to know.
CSL Seqirus data show cell-based flu vaccine provides 20% stronger protection against lab-confirmed influenza
Find out how CSL Seqirus’s real-world data reveal a 20% protection boost for its cell-based flu vaccine over traditional egg-based shots.
Telix Pharmaceuticals (ASX: TLX) jumps 16% after CMS greenlight and Illuccix’s European rollout
Telix Pharmaceuticals raises FY25 revenue guidance after securing CMS reimbursement for Gozellix and accelerating Illuccix's launch in Europe. Learn what’s next.
Pulnovo Medical secures dual IDE approvals with CMS backing to advance PADN clinical trials in the U.S.
Pulnovo Medical gains FDA IDE and CMS coverage to launch PADN U.S. trials, signaling disruption in the pulmonary hypertension device market.
Can PADN technology redefine treatment for pulmonary hypertension? Pulnovo’s trials begin in U.S.
Pulnovo Medical wins FDA IDE approvals and CMS backing for U.S. trials of its PADN system in pulmonary hypertension. Find out what this means for patients.
Can Framer become the new standard in business web design after $2bn valuation boost?
Framer raises $100M at a $2B valuation to transform how businesses build websites. Find out how its AI tools and no-code stack are changing web design.
Bridge to Life’s HOPE clinical trial shows major cost and rejection benefits for liver transplants
Bridge to Life’s HOPE trial shows reduced liver transplant costs and steroid-resistant rejection, strengthening the case for VitaSmart perfusion system adoption.
MiRus earns NTAP approval for EUROPA cervical fusion system, expanding clinical and reimbursement footprint
MiRus receives CMS NTAP approval for its EUROPA Posterior Cervical Fusion System, boosting adoption and access for Medicare patients with spine disorders.